| Research Topics: |
| INDEX |
| AI-chat 1 |
| PRIME 12 |
| aging 6 |
| body 1 |
| brain 7 |
| cancer 5 |
| cognition 2 |
| covid-19 2 |
| culture 2 |
| dental 2 |
| diabetes 1 |
| diagnostics 1 |
| disease 3 |
| genetics 5 |
| heart 8 |
| herbs 1 |
| immune 2 |
| kidneys 2 |
| language 1 |
| lungs 4 |
| metabolism 1 |
| nutrition 2 |
| obesity 1 |
| pain 3 |
| physical 1 |
| politics 2 |
| pollution 1 |
| practice 2 |
| privacy 2 |
| psychology 5 |
| religion 1 |
| reproduction 2 |
| rights 2 |
| sleep 1 |
| vaccine 1 |
| virus 4 |
|
Scanned: 2578 Evaluated: 292 Selected: 56 |
| PRIME COVID-19 | ||||||||
Min10-010 | A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID | |||||||
| Quote: | While AER002 was safe and well tolerated, no significant differences in physical health, quality of life, objective measures of physical function or cognition, or blood-based biomarkers were demonstrated between the treatment and control arms. In a post-hoc analysis, participants with a lower baseline SARS-CoV-2 antibody level and higher drug exposure were more likely to express a perceived treatment benefit based on the Patient Global Impression of Change scale p0.05 for anti-S, S1, and RBD. | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.03.07.26347857v1 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.03.07.26347857v1.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Michael J. Peluso Dylan Ryder Thomas Dalhuisen Danny Hoi Tsun Chu Meghann C. Williams Antonio E. Rodriguez Brian LaFranchi Joanna Vinden Emily A. Fehrman Beatrice Huang Rebecca Hoh Kofi A. Asare Kathleen Bellon Pizarro Mohammad Rahman Emilio de Narvaez Mark M. Painter E. John Wherry Zoe N. Swank Louise L. Hansen David R. Walt Yoshinori Fukazawa Anisha Sekar Steven E. Bellan Holly Tieu Josephat Asiago Prakash Bhuyan Rajeev Venkayya Robert R. Flavell Henry VanBrocklin J. Daniel Kelly Priscilla Y. Hsue Matthew S. Durstenfeld Peter W. Hunt Leonard Calabrese Ma Somsouk Jeffrey N. Martin David V. Glidden Amelia N. Deitchman Timothy J. Henrich Steven G. Deeks, | |||||||
| BRAIN COVID-19 PSYCHOLOGY | ||||||||
Mre10-026 | Assessing Attention Process Training Efficacy in Improving Brain Fog Symptoms in Individuals with Long Covid: A Study Protocol for a Randomized Controlled Trial | |||||||
| Quote: | Conclusions This pilot trial will inform the feasibility and acceptability of APT-3 and generate preliminary efficacy data to guide the design of a future fully powered randomized controlled trial targeting brain fog associated with Long Covid. ### Competing Interest Statement | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.03.10.26348047v1 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.03.10.26348047v1.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Kathryn Magee Elliot Roth Leora R Cherney Shira Cohen-Zimerman, | |||||||
|
Javilk's Research Links for Week 10 Updated 03/15/2026-01:54:15 AM What interests you? What have you found? Tell me! Drop me a note to subscribe or submit something. |